Table 3.
Evaluation of MSC exosomes therapeutic potential in clinical trial registered in ClinicalTrials.gov (January 2021)
| Condition | Study phase | Participant number | Cell source | Cell type | Delivery route | Location | NCT number |
|---|---|---|---|---|---|---|---|
| ARDS | 1/2 | 169 | n.a | Allogeneic | Inhalation | China | NCT04602104 |
| COVID-19 | 1 | 24 | AT | Allogeneic | Inhalation | China | NCT04276987 |
| MODS | n.a | 60 | n.a | Allogeneic | IV | China | NCT04356300 |
| Pulmonary infection | 1/2 | 60 | AT | Allogeneic | Inhalation | China | NCT04544215 |
| AIS | 1/2 | 5 | n.a | Allogeneic | IP | Iran | NCT03384433 |
| Dry eye | 1/2 | 27 | UC | Allogeneic | Inhalation | China | NCT04213248 |
| Macular holes | 1 | 44 | n.a | Allogeneic | Intravitreal | China | NCT03437759 |
| Preeclampsia | n.a | 200 | UC | Allogeneic | n.a | Egypt | NCT03562715 |
| AD | 1/2 | 9 | AT | Allogeneic | Intranasal | China | NCT04388982 |
Note; ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, MODS multiple organ dysfunction syndromes, AIS acute ischemic stroke, AD Alzheimer's diseases, AT adipose tissue, UC umbilical cord, IV intravenous, IP intraperitoneal, n.a not available